Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8223424 | 1.00 | MAPT (0.40) | MAPTL3MBTL1MEN1KMT2AGAA | |
| SCHEMBL4315326 | 0.76 | GAA (0.46) | L3MBTL1GAAPOLBFFAR1HRH3 | |
| SCHEMBL8212499 | 0.76 | GAA (0.46) | L3MBTL1GAAPOLBFFAR1HRH3 | |
| SCHEMBL14247562 | 0.76 | GAA (0.42) | MAPTL3MBTL1MEN1KMT2AGAA | |
| SCHEMBL3236297 | 0.76 | GAA (0.42) | MAPTL3MBTL1MEN1KMT2AGAA | |
| SCHEMBL29544886 | 0.76 | GAA (0.42) | MAPTL3MBTL1MEN1KMT2AGAA | |
| SCHEMBL22555731 | 0.75 | MAPT (0.40) | MAPTL3MBTL1MEN1KMT2AGAA | |
| SCHEMBL3232212 | 0.70 | GAA (0.43) | MAPTL3MBTL1MEN1KMT2AGAA | |
| SCHEMBL24635866 | 0.70 | CHRNB2 (0.68) | L3MBTL1GAACHRNB2CHRNA4 | |
| SCHEMBL24028246 | 0.70 | CHRNB2 (0.68) | L3MBTL1GAACHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049110-B1 | BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-08-20 | — | — | EP | disclosed |
| EP-2049110-B1 | BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-08-20 | — | — | EP | disclosed |
| US-8618102-B2 | Bridged diazepan orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-12-31 | — | — | US | disclosed |
| US-20090239843-A1 | Bridged diazepan orexin receptor antagonists | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | disclosed |
| US-20090239843-A1 | Bridged diazepan orexin receptor antagonists | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239843-A1 | Bridged diazepan orexin receptor antagonists | HCRTR2, HCRTR1, CRHR1 | MAPT 620/4885L3MBTL1 4413/4885MEN1 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.